Name: | Tramadol |
---|---|
PubChem Compound ID: | 10017651 |
Description: | A narcotic analgesic proposed for severe pain. It may be habituating. |
Molecular formula: | C16H26ClNO2 |
Molecular weight: | 299.836 g/mol |
Name: | Tramadol |
---|---|
Name (isomeric): | DB00193 |
Drug Type: | small molecule |
Description: | A narcotic analgesic proposed for severe pain. It may be habituating. |
Synonyms: |
Tramadol hydrochloride; Tramodol Hcl; Tramadolum [INN-Latin]; Tramadol HCl
|
Brand: | Ultram, Tramadol HCl BP/EP, Ultram ER, Crispin, Ralivia Flashtab, Tridural, Tramal, Ralivia ER, Zydol |
Category: | Narcotics, Analgesics, Analgesics, Opioid |
CAS number: | 27203-92-5 |
Indication: | Indicated in the treatment of moderate to severe pain. Consider for those prone to constipation or respiratory depression. Tramadol is used to treat postoperative, dental, cancer, and acute musculosketetal pain and as an adjuvant to NSAID therapy in patients with osteoarthritis. |
---|---|
Pharmacology: | Tramadol, a centrally-acting analgesic, exists as a racemic mixture of the trans isomer, with important differences in binding, activity, and metabolism associated with the two enantiomers. Although Tramadol is a synthetic analog of codeine, it has a significantly lower affinity for opioid receptors than codeine. |
Mechanism of Action: |
Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface...
show more » |
Absorption: | Racemic tramadol is rapidly and almost completely absorbed after oral administration. The mean absolute bioavailability of a 100 mg oral dose is approximately 75%.The mean peak plasma concentration of racemic tramadol and M1 occurs at two and three hours, respectively, after administration in healthy adults. |
Protein binding: | 20% |
Biotransformation: | The major metabolic pathways appear to be N- and O- demethylation and glucuronidation or sulfation in the liver. One metabolite (O-desmethyltramadol, denoted M1) is pharmacologically active in animal models. |
Route of elimination: | Tramadol is eliminated primarily through metabolism by the liver and the metabolites are eliminated primarily by the kidneys. Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites. |
Half Life: | 23 +/- 10 minutes |
Clearance: | 5.9 mL/min/Kg [Healthy Adults, 100 mg qid, MD p.o] 8.5 mL/min/Kg [Healthy Adults, 100 mg SD p.o] 6.89 mL/min/Kg [Geriatric, (<75 yr), 50 mg SD p.o.] 4.23 mL/min/Kg [Hepatic Impaired, 50 mg SD p.o.] 4.23 mL/min/Kg [Renal Impaired, Clcr10-3mL/min, 100 mg SD i.v.] 3.73 mL/min/Kg [Renal Impaired, CLcr<5 mL/min, 100 mg SD i.v.] 6.4 mL/min/Kg [Male following a 100 mg IV dose] 5.7 mL/min/Kg [Female following a 100 mg IV dose] |
Toxicity: | LD50=350mg/kg (orally in mice) |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|